Dr. Anil Singhal is currently the President and Chief Executive Officer of Trishula Therapeutics, a privately held, clinical-stage company developing TTX-030, a CD39 antibody in multiple solid tumors. Previously, he held a similar role at Adicet Bio, a company developing allogeneic cell therapy in cancer. He joined Adicet from Canaan Partners where he served as Executive in Residence and OncoResponse Inc., where he served as Chief Scientific Officer. He is the former Vice President of Early Oncology Development of AbbVie and Head of its Abbvie-Redwood City, California site. During his tenure at AbbVie, Anil oversaw the global regulatory approval of Empliciti in multiple myeloma and Daclizumab in multiple sclerosis. As a member of the R&D leadership team, he helped to guide an impressive portfolio and key translational science capabilities in oncology and other diseases.
Anil has held senior roles in the U.S., Japanese and German biopharma/biotechnology industry leading to the approvals of Prosorba in auto-immune disease and talaporfin sodium in non-small cell lung cancer. Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at the University of Washington.
